Please ensure Javascript is enabled for purposes of website accessibility

Why Valeant Pharmaceuticals Stock Fell 11% in January

By George Budwell - Feb 14, 2018 at 2:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Wall Street is starting to doubt Valeant's comeback plan.

What happened

Valeant Pharmaceuticals (BHC 4.47%) stock started the year off on a sour note by shedding nearly 11% of its value in January, according to S&P Global Market Intelligence . What's behind this double-digit drop?

The specialty pharma's stock tumbled immediately after analysts at Goldman Sachs issued a dreaded sell rating on the company's shares. Goldman's pessimistic outlook reportedly stems from the company's high debt load, new competitive threats to its product portfolio, and the risk of outstanding lawsuits eventually resulting in sizable financial penalties. 

Chalkboard drawing of a positive trend turning negative.

Image source: Getty Images.

So what

Up until now, CEO Joseph Papa has done an admirable job of turning Valeant around in the face of these daunting challenges. Since taking over, for instance, Papa has paid down over $6 billion in debt ahead of schedule, and he has done so without parting with core segments such as the eye-care unit Bausch & Lomb or its Salix business. 

In response, Valeant's stock has more than doubled in value since hitting an all-time low only last May. Goldman's analysts, however, obviously think that Valeant's rebound is starting to run out of steam. 

Now what

During Valeant's upcoming Q4 earnings call scheduled for Feb. 28, we should learn a lot more about Papa's plans to continue deleveraging the company in a sustainable manner -- or whether this scenario is even possible. The long and short of it is that Valeant's free cash flow simply isn't enough to make a major dent in its ginormous debt load, which presently stands at $25.5 billion.

The company also can't keep plowing most of its free cash flow into just paying debt. At some point, Valeant must invest significantly more in research and development than it traditionally has in the past in order to generate long-term growth. Valeant, after all, doesn't have the financial flexibility to pursue any bolt-on acquisitions at this stage. 

Bottom line: Valeant is nearing an inflection point that may force the company to divest a core asset to service its debt. If that happens, there's no telling where this struggling drugmaker's story will end.

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Valeant Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
BHC
$5.84 (4.47%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.